News
January 7, 2008 - Osiris Therapeutics Inc. has reclaimed sole worldwide rights to cardiovascular indications for Prochymal and terminated its development and commercialization agreement with Boston Scientific Corp. in order to provide Osiris with the flexibility to enter more strategically beneficial relationships.
January 06, 2008
News
January 7, 2008 – Patients with atrial flutter and atrial fibrillation may require additional sites of ablation to ...
January 06, 2008News
January 7, 2008 - Abiomed Inc. has rolled out a new Portable Circulatory Support Driver for both in-hospital and out-of ...
January 06, 2008Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024News
January 7, 2008 - An on-line vascular health activity book that teaches children ages 5-12 how their vascular system ...
January 06, 2008News
January 7, 2008 - Cardica Inc. received nearly $2 million in payments from Cook Medical (Cook) for reaching milestones pursuant to its development agreements with Cook, including a vascular closure device collaboration agreement and initial development milestone for a device to repair heart defects.
January 06, 2008News
January 7, 2008 - Imaging for early cardiovascular disease that causes heart attack and stroke is the focus of the High ...
January 06, 2008Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024News
January 7, 2008 - Boston Scientific Corp. has completed the sale of its Cardiac Surgery and Vascular Surgery businesses ...
January 06, 2008News
January 3, 2008 - A study reported in the Jan. 3 New England Journal of Medicine found that one third of patients who ...
January 03, 2008News
January 3, 2008 - Medical Simulation Corp. and Edwards Lifesciences Corp. will launch the Edwards SAPIEN Transcatheter ...
January 02, 2008Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023News
January 3, 2008 – Abiomed Inc. selected Tufts-New England Medical Center (Tufts-NEMC) as a “Center of Excellence” for ...
January 02, 2008News
January 3, 2008 - A patient’s physical activity status is a significant and robust predictor of all-cause mortality in ...
January 02, 2008News
January 3, 2008 - A modular stent graft that inserts multiple, caudally-directed branches to the visceral arteries to ...
January 02, 2008Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023News
January 2, 2008 – Allergic-like reactions to gadolinium-containing contrast injections in adults and pediatric patients ...
January 01, 2008News
December 29, 2007 - Boston Scientific Corp. received CE Mark approval for its LIVIAN cardiac resynchronization therapy defibrillator (CRT-D), which treats heart failure and is designed to help protect patients at risk of sudden cardiac death by monitoring heartbeats in heart failure patients and delivering small electrical impulses that may improve the heart’s pumping ability.
December 27, 2007News
December 28, 2007 - The data converter and amplifiers market for portable imaging systems will reach $582.7 million in ...
December 27, 2007© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now